| Literature DB >> 30348863 |
Andrew G Cox1, Allison Tsomides2, Dean Yimlamai3, Katie L Hwang2,4, Joel Miesfeld5, Giorgio G Galli3, Brendan H Fowl3, Michael Fort2, Kimberly Y Ma2, Mark R Sullivan6, Aaron M Hosios6, Erin Snay3, Min Yuan7, Kristin K Brown7, Evan C Lien6,7, Sagar Chhangawala8, Matthew L Steinhauser2,9,10, John M Asara7, Yariv Houvras8, Brian Link5, Matthew G Vander Heiden6,11, Fernando D Camargo3,9, Wolfram Goessling1,9,10,11,12.
Abstract
The Hippo pathway and its nuclear effector Yap regulate organ size and cancer formation. While many modulators of Hippo activity have been identified, little is known about the Yap target genes that mediate these growth effects. Here, we show that yap -/- mutant zebrafish exhibit defects in hepatic progenitor potential and liver growth due to impaired glucose transport and nucleotide biosynthesis. Transcriptomic and metabolomic analyses reveal that Yap regulates expression of glucose transporter glut1, causing decreased glucose uptake and use for nucleotide biosynthesis in yap -/- mutants, and impaired glucose tolerance in adults. Nucleotide supplementation improves Yap deficiency phenotypes, indicating functional importance of glucose-fueled nucleotide biosynthesis. Yap-regulated glut1 expression and glucose uptake are conserved in mammals, suggesting that stimulation of anabolic glucose metabolism is an evolutionarily conserved mechanism by which the Hippo pathway controls organ growth. Together, our results reveal a central role for Hippo signaling in glucose metabolic homeostasis.Entities:
Keywords: Hippo pathway; Yap; glucose metabolism; glut1; liver development
Mesh:
Substances:
Year: 2018 PMID: 30348863 PMCID: PMC6236334 DOI: 10.15252/embj.2018100294
Source DB: PubMed Journal: EMBO J ISSN: 0261-4189 Impact factor: 11.598